1Burris KD,Molski TF,Xu C,et al.Aripiprazole,a novel antipsychotic,is a high-affinity partial agonist at human dopamine D2 receptors.J Pharmacol Exp Ther,2002,302(3):381～389.
2Kane JM,Carson WH,Saha AR,et al.Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder.J Clin Psychiatry,2002,63 (5):763～771.
3Saha AR,Carson WH,AH MW,et al.Efficacy and safety of aripiprazole and risperidone vs.placebo in patients with schizophrenia and schizoaffectective disorder.WJ Biol Psychiatry,2001,2 (Suppl 1):305.
4Lieberman J,Carson WH,Saha AR,et al.Meta-analysis of the efficacy of aripiprazole in schizophrenia.Int J Neuropsychopharmacol,2002,5(Suppl 1):186.
5Petrel JL,Saha AR Mcecoy JP.Aripiprazole,a new atypical antipsychotic:overview of phase results poster.Presented at the 36th annual meeting of the American College of Neuropsychopharmacology,Walkloa,Hawaii,1997.8～12.
9Patel N C, Sierk P, Dorson P G, et al. Experience with ziprasidone[ J ]. J Am Acad Chil Adolesc Psychiatry,2002,41 (5):495-498.
10Annenteros J L, Whitaker A H, Welikson M, et al. Risperidone in adolescents with schizophrenia: an open pilot study[J]. J Am Acad Child Adolesc Psychiatry, 1997,36 (5) : 694-700.
